Kim JW, Kim HJ, Heo K, Lee Y, Jang HJ, Lee HY, Park JW, Cho YB, Lee JH, Shin HG, Yang HR, Choi HL, Shim HB, Lee S. A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants. Front Immunol. 2023;14:1271508.

 

Kim HJ, Chang HK, Lee YM, Heo K*. Catecholamine promote ovarian cancer progression through secretion of CXC-chemokines. Int J Mol Sci. 2023;24(18):14104. *corresponding author

​

Choi MS, Kim JH, Lee CY, Lee YM, Lee S, Chang HK, Kim HJ*, Heo K*. Gentian Violet Inhibits Cell Proliferation through Induction of Apoptosis in Ovarian Cancer Cells. Biomedicines. 2023;11(6):1657. *co-corresponding authors

​

Ko M, Kim HJ, Park J, Lee H, Lee KN, Kim K, Lee J, Yoon SJ, Kim T, Jeong S, Heo K, Lee YK, Do YR. Isolation of Bovine Milk Exosome Using Electrophoretic Oscillation Assisted Tangential Flow Filtration with Antifouling of Micro-ultrafiltration Membrane Filters. ACS Appl Mater Interfaces. 2023;15(21):26069-26080.

​

Choi SI, Lee YS, Lee YM, Kim HJ, Kim WJ, Jung S, Im JE, Lee MR, Kim JK, Jeon AR, Woo SM, Oh GT, Heo K*, Kim YH*, Kim IH.​ Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment. J Control Release. 2023;360:940-952. *co-corresponding authors

​

Kim JW*, Heo K*, Kim HJ, Yoo Y, Cho HS, Jang HJ, Lee HY, Ko IY, Woo JR, Cho YB, Lee JH, Yang HR, Shin HG, Choi HL, Hwang K, Kim S, Kim H, Chun K, Lee S. Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants. Antiviral Res. 2023;212:105576. *co-first authors

​

Cho YB, Kim JW, Heo K, Kim HJ, Yun S, Lee HS, Shin HG, Shim H, Yu H, Kim YH, Lee S.Lee S. An internalizing antibody targeting of cell surface GRP94 effectively suppresses tumor angiogenesis of colorectal cancer. Biomed Pharmacother. 2022;150:113051.

​

Kim HJ, Heo K*. YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation. Anticancer Res. 2021;41(2):671-678. *corresponding author

​

Kim HJ, Sung HJ, Lee YM, Choi SI, Kim YH, Heo K*, Kim IH*. Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody). Int J Mol Sci. 2020;21(9):3286. *co-corresponding authors

​

Heo K, Lee S. TSPAN8 as a Novel Emerging Therapeutic Target in Cancer for Monoclonal Antibody Therapy. Biomolecules. 2020;10(3):388.

​

Jeoung MH, Kim TK, Kim JW, Cho YB, Na HJ, Yoo BC, Shim H, Song DK, Heo K, Lee S. Antibody-Based Targeting of Cell Surface GRP94 Specifically Inhibits Cetuximab-Resistant Colorectal Cancer Growth. Biomolecules. 2019;9(11):681.

​​

Kim HJ, Lee S, Oh YS, Chang HK, Kim YS, Hong SH, Kim JY, Park YW, Lee SJ, Song SW, Kim JJ, Heo K*. Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression. Front Oncol. 2019;9:571. *corresponding author

​

Park J, Jang JH, Oh S, Kim M, Shin C, Jeong M, Heo K, Park JB, Kim SR, Oh YS. LPA-induced migration of ovarian cancer cells requires activation of ERM proteins via LPA1 and LPA2. Cell Signal. 2018;44:138-147.

 

Kim TK, Park CS, Jang J, Kim MR, Na HJ, Lee K, Kim HJ, Heo K, Yoo BC, Kim YM, Lee JW, Kim SJ, Kim ES, Kim DY, Cha K, Lee TG, Lee S. Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a. Mol Oncol. 2018;12(3):356-372.

 

Yin J, Jung JE, Choi SI, Kim SS, Oh YT, Kim TH, Choi E, Lee SJ, Kim H, Kim EO, Lee YS, Chang HJ, Park JY, Kim Y, Yun T, Heo K, Kim YJ, Kim H, Kim YH, Park JB, Choi SW. Inhibition of BMP signaling overcomes acquired resistance to cetuximab in oral squamous cell carcinomas. Cancer Lett. 2018;414:181-189.

 

Jang J, Kim MR, Kim TK, Lee WR, Kim JH, Heo K, Lee S. CLEC14a-HSP70-1A interaction regulates HSP70-1A-induced angiogenesis. Sci Rep. 2017;7(1):10666.

 

Oh YS, Heo K, Kim EK, Jang JH, Bae SS, Park JB, Kim YH, Song M, Kim SR, Ryu SH, Kim IH, Suh PG. Dynamic relocalization of NHERF1 mediates chemotactic migration of ovarian cancer cells toward lysophosphatidic acid stimulation. Exp Mol Med. 2017;49(7):e351.

 

Lee YJ, Shin KJ, Park SA, Park KS, Park S, Heo K, Seo YK, Noh DY, Ryu SH, Suh PG. G-protein-coupled receptor 81 promotes a malignant phenotype in breast cancer through angiogenic factor secretion. Oncotarget. 2016;7(43):70898-70911.

 

Kim S, Sung HJ, Lee JW, Kim YH, Oh YS, Yoon KA, Heo K*, Suh PG*. C-terminally mutated tubby protein accumulates in aggresomes. BMB Rep. 2017;50(1):37-42. *co-corresponding authors

 

Heo K, Min SW, Sung HJ, Kim HG, Kim HJ, Kim YH, Choi BK, Han S, Chung S, Lee ES, Chung J, Kim IH. An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies. J Control Release. 2016;229:1-9

 

Park CS, Kim TK, Kim HG, Kim YJ, Jeoung MH, Lee WR, Go NK, Heo K*, Lee S*. Therapeutic targeting of tetraspanin8 in epithelial ovarian cancer invasion and metastasis. Oncogene. 2016; 35(34):4540-8. *co-corresponding authors

 

Li KC*, Heo K*, Ambade N, Kim MK, Kim KH, Yoo BC, Yoo HS. Reduced expression of HSP27 following HAD-B treatment is associated with Her2 downregulation in NIH:OVCAR-3 human ovarian cancer cells. Mol Med Rep. 2015;12(3):3787-94. *co-first authors

 

Lee JW, Kim HJ, Heo K*. Therapeutic aptamers: developmental potential as anticancer drugs. BMB Rep. 2015;48(4):234-7. *corresponding author

 

Kim YH, Moon JY, Kim EO, Lee SJ, Kang SH, Kim SK, Heo K, Lee Y, Kim H, Kim KT, Kim D, Song MS, Lee SW, Lee Y, Koh SS, Kim IH. Efficient targeting and tumor retardation effect of pancreatic adenocarcinoma up-regulated factor (PAUF)-specific RNA replacement in pancreatic cancer mouse model. Cancer Lett. 2014;344(2):223-31.

 

Sung HJ, Choi S, Lee JW, Ok CY, Bae YS, Kim YH, Lee W*, Heo K*, Kim IH. Inhibition of human neutrophil activity by an RNA aptamer bound to interleukin-8. Biomaterials. 2014;35(1):578-89. *co-corresponding authors

 

Hwang JA, Lee BB, Kim Y, Park SE, Heo K, Hong SH, Kim YH, Han J, Shim YM, Lee YS, Kim DH. HOXA11 hypermethylation is associated with progression of non-small cell lung cancer. Oncotarget. 2013;4(12):2317-25.

 

Heo K*, Kim YH*, Sung HJ, Li HY, Yoo CW, Kim JY, Park JY, Lee UL, Nam BH, Kim EO, Kim SY, Lee SH, Park JB, Choi SW. Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. Oral Oncol. 2012;48(6):500-6. *co-first authors

 

Sung HJ, Han JI, Lee JW, Uhm KB, Heo K*. TCCR/WSX-1 is a novel angiogenic factor in age-related macular degeneration. Mol Vis. 2012;18:234-40. *corresponding author

 

Kim YH, Sung HJ, Kim S, Kim EO, Lee JW, Moon JY, Choi K, Jung JE, Lee Y, Koh SS, Rhee SG, Heo K*, Kim IH*. An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. Cancer Lett. 2011;313(1):76-83. *co-corresponding authors

 

Choi JW, Lim S, Oh YS, Kim EK, Kim SH, Kim YH, Heo K, Kim J, Kim JK, Yang YR, Ryu SH, Suh PG. Subtype-specific role of phospholipase C-beta in bradykinin and LPA signaling through differential binding of different PDZ scaffold proteins. Cell Signal. 2010;22(7):1153-61.

 

Chae YC, Lee S, Heo K, Ha SH, Jung Y, Kim JH, Ihara Y, Suh PG, Ryu SH. Collapsin response mediator protein-2 regulates neurite formation by modulating tubulin GTPase activity. Cell Signal. 2009;21(12):1818-26.

 

Heo K, Park KA, Kim YH, Kim SH, Oh YS, Kim IH, Ryu SH, Suh PG. Sphingosine 1-phosphate induces vascular endothelial growth factor expression in endothelial cells. BMB Rep. 2009;42(10):685-90.

 

Lim S, Choi JW, Kim HS, Kim YH, Yea K, Heo K, Kim JH, Kim SH, Song M, Kim JI, Ryu SH, Suh PG. A myristoylated pseudosubstrate peptide of PKC-zeta induces degranulation in HMC-1 cells independently of PKC-zeta activity. Life Sci. 2008;82(13-14):733-40.

 

Kim SH, Kim YH, Song M, An SH, Byun HY, Heo K, Lim S, Oh YS, Ryu SH, Suh PG. O-GlcNAc modification modulates the expression of osteocalcin via OSE2 and Runx2. Biochem Biophys Res Commun. 2007;362(2):325-9.

 

Heo K, Ha SH, Chae YC, Lee S, Oh YS, Kim YH, Kim SH, Kim JH, Mizoguchi A, Itoh TJ, Kwon HM, Ryu SH, Suh PG. RGS2 promotes formation of neurites by stimulating microtubule polymerization. Cell Signal. 2006;18(12):2182-92.

 

Kim YH, Song M, Oh YS, Heo K, Choi JW, Park JM, Kim SH, Lim S, Kwon HM, Ryu SH, Suh PG. Inhibition of phospholipase C-beta1-mediated signaling by O-GlcNAc modification. J Cell Physiol. 2006;207(3):689-96.

 

Chae YC, Lee S, Lee HY, Heo K, Kim JH, Kim JH, Suh PG, Ryu SH. Inhibition of muscarinic receptor-linked phospholipase D activation by association with tubulin. J Biol Chem. 2005;280(5):3723-30.

 

Oh YS, Jo NW, Choi JW, Kim HS, Seo SW, Kang KO, Hwang JI, Heo K, Kim SH, Kim YH, Kim IH, Kim JH, Banno Y, Ryu SH, Suh PG. NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation. Mol Cell Biol. 2004;24(11):5069-79.

 

Bae YS, Lee TG, Park JC, Hur JH, Kim Y, Heo K, Kwak JY, Suh PG, Ryu SH. Identification of a compound that directly stimulates phospholipase C activity. Mol Pharmacol. 2003;63(5):1043-50.

 

Mizoguchi A, Nakanishi H, Kimura K, Matsubara K, Ozaki-Kuroda K, Katata T, Honda T, Kiyohara Y, Heo K, Higashi M, Tsutsumi T, Sonoda S, Ide C, Takai Y. Nectin: an adhesion molecule involved in formation of synapses. J Cell Biol. 2002;156(3):555-65.

 

Lee S, Kim JH, Lee CS, Kim JH, Kim Y, Heo K, Ihara Y, Goshima Y, Suh PG, Ryu SH. Collapsin response mediator protein-2 inhibits neuronal phospholipase D(2) activity by direct interaction. J Biol Chem. 2002;277(8):6542-9.

 

Hwang JI, Heo K, Shin KJ, Kim E, Yun C, Ryu SH, Shin HS, Suh PG. Regulation of phospholipase C-beta 3 activity by Na+/H+ exchanger regulatory factor 2. J Biol Chem. 2000;275(22):16632-7.